The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis

被引:3
|
作者
Frascoli, Federico [1 ]
Roos, Izanne [2 ,3 ]
Malpas, Charles B. [2 ,3 ]
Kalincik, Tomas [2 ,3 ]
机构
[1] Swinburne Univ Technol, Dept Math, Fac Sci Comp & Engn Technol, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, CORe, Melbourne, Vic 3050, Australia
[3] Royal Melbourne Hosp, Melbourne MS Ctr, Dept Neurol, Melbourne, Vic 3050, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Population models; Multiple sclerosis; Drug trials; MATHEMATICAL-MODEL; ASSOCIATION; THERAPY; MRI;
D O I
10.1016/j.jtbi.2022.111091
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for the response to disease modifying therapies is proposed. With a population approach and separate states for patients accounting for their risk of relapses, a system of nonlinear equations is formulated, similarly to established epidemiological models. Different parameters describe the effect of drugs and treatment switch in reducing the frequency of relapses. The model allows for a good fit to previously published data for experiments where different drugs are used. It also shows that different treatments maintain a high degree of similarity, with analogous dynamical features: a pre-treatment increment in relapse frequency leading to a distinct peak, a rapid drop after treatment switch and a plateau corresponding to a new base relapse activity, which seems dependant on the treatment chosen. A sensitivity analysis shows that the uncertainty in the initial proportions of different populations and the frequency of relapses can modify the overall dynamics of the response to treatment. Drugs are observed to induce effects that depend on patient sample's intrinsic characteristics, producing two clearly distinct and independent dynamics of relapse response. This confirms the clinical observation that certain drugs may be overall more successful in lowering the rate of relapses more significantly than others, notwithstanding the fact that patients behave differently across experiments. (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Oral simvastatin treatment in relapsing-remitting multiple sclerosis
    Vollmer, T
    Key, L
    Durkalski, V
    Tyor, W
    Corboy, J
    Markovic-Plese, S
    Preiningerova, J
    Rizzo, M
    Singh, L
    LANCET, 2004, 363 (9421): : 1607 - 1608
  • [22] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [23] Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kurukulasuriya, Nuwan C.
    Greenberg, Steven J.
    Scaramozza, Matthew
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 123 - 136
  • [24] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Jens Ingwersen
    Orhan Aktas
    Hans-Peter Hartung
    Neurotherapeutics, 2016, 13 : 47 - 57
  • [25] Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
    Kalincik, Tomas
    Horakova, Dana
    Spelman, Tim
    Jokubaitis, Vilija
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Rozsa, Csilla
    Grammond, Pierre
    Alroughani, Raed
    Duquette, Pierre
    Girard, Marc
    Pucci, Eugenio
    Lechner-Scott, Jeannette
    Slee, Mark
    Fernandez-Bolanos, Ricardo
    Grand'Maison, Francois
    Hupperts, Raymond
    Verheul, Freek
    Hodgkinson, Suzanne
    Oreja-Guevara, Celia
    Spitaleri, Daniele
    Barnett, Michael
    Terzi, Murat
    Bergamaschi, Roberto
    McCombe, Pamela
    Sanchez-Menoyo, Jose
    Simo, Magdolna
    Csepany, Tunde
    Rum, Gabor
    Boz, Cavit
    Havrdova, Eva
    Butzkueven, Helmut
    ANNALS OF NEUROLOGY, 2015, 77 (03) : 425 - 435
  • [26] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [27] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [28] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [29] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [30] Serum uric acid levels are decreased in patients with relapsing-remitting multiple sclerosis, in particular during relapses
    Tsakiri, Anna
    Tsiantoulas, Dimitris
    Frederiksen, Jette
    MULTIPLE SCLEROSIS, 2008, 14 : S289 - S289